These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1673 related items for PubMed ID: 22052584

  • 21. Impact of noncompliance with urate-lowering drug on serum urate and gout-related healthcare costs: administrative claims analysis.
    Halpern R, Mody RR, Fuldeore MJ, Patel PA, Mikuls TR.
    Curr Med Res Opin; 2009 Jul; 25(7):1711-9. PubMed ID: 19485724
    [Abstract] [Full Text] [Related]

  • 22. Efficacy and tolerability of febuxostat in hyperuricemic patients with or without gout: a systematic review and meta-analysis.
    Ye P, Yang S, Zhang W, Lv Q, Cheng Q, Mei M, Luo T, Liu L, Chen S, Li Q.
    Clin Ther; 2013 Feb; 35(2):180-9. PubMed ID: 23332451
    [Abstract] [Full Text] [Related]

  • 23. Febuxostat for prevention of gout attacks.
    Pohar S, Murphy G.
    Issues Emerg Health Technol; 2006 Aug; (87):1-4. PubMed ID: 16958189
    [Abstract] [Full Text] [Related]

  • 24. Safety and efficacy of febuxostat treatment in subjects with gout and severe allopurinol adverse reactions.
    Chohan S.
    J Rheumatol; 2011 Sep; 38(9):1957-9. PubMed ID: 21724706
    [Abstract] [Full Text] [Related]

  • 25. Safety and efficacy of oral febuxostat for treatment of HLA-B*5801-negative gout: a randomized, open-label, multicentre, allopurinol-controlled study.
    Yu KH, Lai JH, Hsu PN, Chen DY, Chen CJ, Lin HY.
    Scand J Rheumatol; 2016 Jul; 45(4):304-11. PubMed ID: 26771445
    [Abstract] [Full Text] [Related]

  • 26. An allopurinol-controlled, multicenter, randomized, open-label, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 2 exploratory clinical study.
    Kamatani N, Fujimori S, Hada T, Hosoya T, Kohri K, Nakamura T, Ueda T, Yamamoto T, Yamanaka H, Matsuzawa Y.
    J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S44-9. PubMed ID: 21654269
    [Abstract] [Full Text] [Related]

  • 27. Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout.
    Ernst ME, Fravel MA.
    Clin Ther; 2009 Nov; 31(11):2503-18. PubMed ID: 20109996
    [Abstract] [Full Text] [Related]

  • 28. Rilonacept (interleukin-1 trap) in the prevention of acute gout flares during initiation of urate-lowering therapy: results of a phase II randomized, double-blind, placebo-controlled trial.
    Schumacher HR, Sundy JS, Terkeltaub R, Knapp HR, Mellis SJ, Stahl N, Yancopoulos GD, Soo Y, King-Davis S, Weinstein SP, Radin AR, 0619 Study Group.
    Arthritis Rheum; 2012 Mar; 64(3):876-84. PubMed ID: 22223180
    [Abstract] [Full Text] [Related]

  • 29. Multicenter, open-label study of long-term administration of febuxostat (TMX-67) in Japanese patients with hyperuricemia including gout.
    Kamatani N, Fujimori S, Hada T, Hosoya T, Kohri K, Nakamura T, Ueda T, Yamamoto T, Yamanaka H, Matsuzawa Y.
    J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S50-6. PubMed ID: 21654270
    [Abstract] [Full Text] [Related]

  • 30. A phase 3, multicenter, randomized, allopurinol-controlled study assessing the safety and efficacy of oral febuxostat in Chinese gout patients with hyperuricemia.
    Xu S, Liu X, Ming J, Chen S, Wang Y, Liu X, Liu H, Peng Y, Wang J, Lin J, Ji H, Liu B, Lu Y, Liu P, Zhang Y, Ji Q.
    Int J Rheum Dis; 2015 Jul; 18(6):669-78. PubMed ID: 26013187
    [Abstract] [Full Text] [Related]

  • 31. Comparative effectiveness of urate lowering with febuxostat versus allopurinol in gout: analyses from large U.S. managed care cohort.
    Singh JA, Akhras KS, Shiozawa A.
    Arthritis Res Ther; 2015 May 12; 17(1):120. PubMed ID: 25963969
    [Abstract] [Full Text] [Related]

  • 32. Efficacy of febuxostat versus allopurinol and the predictors of achieving target serum urate in a cohort of Thai people with gout.
    Lertnawapan R, Jatuworapruk K.
    Clin Rheumatol; 2021 Jan 12; 40(1):255-262. PubMed ID: 32607660
    [Abstract] [Full Text] [Related]

  • 33. Comparison of efficacy and safety of urate-lowering therapies for hyperuricemic patients with gout: a meta-analysis of randomized, controlled trials.
    Fan M, Liu J, Zhao B, Wu X, Li X, Gu J, Schlesinger N.
    Clin Rheumatol; 2021 Feb 12; 40(2):683-692. PubMed ID: 32654080
    [Abstract] [Full Text] [Related]

  • 34. Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout.
    Dalbeth N, Kumar S, Stamp L, Gow P.
    J Rheumatol; 2006 Aug 12; 33(8):1646-50. PubMed ID: 16783857
    [Abstract] [Full Text] [Related]

  • 35. Febuxostat efficacy in allopurinol-resistant tophaceous gout.
    Uh M, Reid G.
    J Clin Rheumatol; 2011 Jun 12; 17(4):204-6. PubMed ID: 21617552
    [Abstract] [Full Text] [Related]

  • 36. African American patients with gout: efficacy and safety of febuxostat vs allopurinol.
    Wells AF, MacDonald PA, Chefo S, Jackson RL.
    BMC Musculoskelet Disord; 2012 Feb 09; 13():15. PubMed ID: 22316106
    [Abstract] [Full Text] [Related]

  • 37. Serum urate levels and gout flares: analysis from managed care data.
    Sarawate CA, Patel PA, Schumacher HR, Yang W, Brewer KK, Bakst AW.
    J Clin Rheumatol; 2006 Apr 09; 12(2):61-5. PubMed ID: 16601538
    [Abstract] [Full Text] [Related]

  • 38. Placebo-controlled double-blind dose-response study of the non-purine-selective xanthine oxidase inhibitor febuxostat (TMX-67) in patients with hyperuricemia (including gout patients) in japan: late phase 2 clinical study.
    Kamatani N, Fujimori S, Hada T, Hosoya T, Kohri K, Nakamura T, Ueda T, Yamamoto T, Yamanaka H, Matsuzawa Y.
    J Clin Rheumatol; 2011 Jun 09; 17(4 Suppl 2):S35-43. PubMed ID: 21654268
    [Abstract] [Full Text] [Related]

  • 39. Placebo-controlled, double-blind study of the non-purine-selective xanthine oxidase inhibitor Febuxostat (TMX-67) in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study.
    Kamatani N, Fujimori S, Hada T, Hosoya T, Kohri K, Nakamura T, Ueda T, Yamamoto T, Yamanaka H, Matsuzawa Y.
    J Clin Rheumatol; 2011 Jun 09; 17(4 Suppl 2):S19-26. PubMed ID: 21654266
    [Abstract] [Full Text] [Related]

  • 40. Febuxostat: new drug. Hyperuricaemia: risk of gout attacks.
    Prescrire Int; 2009 Apr 09; 18(100):63-5. PubMed ID: 19585722
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 84.